A Randomized, Double Blind, Multicenter, Multinational, Placebo Controlled, Parallel Group, Single Dose, Adaptive Efficacy and Safety Study of Glenzocimab Used as an add-on Therapy on Top of Standard of Care un the 4.5 Hours Following an Acute Ischemic Stroke
Latest Information Update: 22 Sep 2024
At a glance
- Drugs Glenzocimab (Primary)
- Indications Stroke
- Focus Registrational; Therapeutic Use
- Acronyms ACTISAVE
- Sponsors Acticor Biotech
- 15 Mar 2024 Status changed from active, no longer recruiting to completed.
- 30 Nov 2023 Planned End Date changed from 30 Dec 2025 to 31 Jan 2024.
- 30 Nov 2023 Planned primary completion date changed from 30 Jun 2025 to 31 Jan 2024.